|
Re: CRISPR vs. BET inhibitors
|
2
|
Resverlogix Corp.
|
Jan 11, 2016 03:48PM
|
|
Re: A Shenzhen Hepalink M&A type deal...
|
2
|
Resverlogix Corp.
|
Jan 05, 2018 06:27PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 01, 2018 05:17PM
|
|
Re: Zenith poster from AACR EORTC meeting and Annual General/Special meeting date
|
2
|
Resverlogix Corp.
|
Nov 16, 2015 11:54AM
|
|
Re: Interesting.
|
2
|
Resverlogix Corp.
|
Nov 23, 2021 11:39AM
|
|
Re: Another Report of Exempt Distribution
|
2
|
Resverlogix Corp.
|
Mar 19, 2023 08:35PM
|
|
Re: TSX Review
|
2
|
Resverlogix Corp.
|
Mar 13, 2018 09:02PM
|
|
Hepalink buys Cytovance Biologics
|
2
|
Resverlogix Corp.
|
Aug 24, 2015 05:00PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 05:45PM
|
|
Re: Q2 Zenith/Resverlogix Events
|
2
|
Zenith Epigenetics
|
Apr 12, 2016 05:10PM
|
|
Re: OTC Trading questions
|
2
|
Zenith Epigenetics
|
Mar 03, 2022 12:04PM
|
|
What if RRR MACE is significant at 90% confidence?
|
2
|
Resverlogix Corp.
|
Apr 23, 2018 03:16PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:10PM
|
|
Re: China, China, China
|
2
|
Resverlogix Corp.
|
Aug 31, 2017 09:15PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 06, 2018 01:15PM
|
|
Re: Covid study
|
2
|
Resverlogix Corp.
|
Feb 13, 2024 10:56AM
|
|
Vote reminder
|
2
|
Zenith Epigenetics
|
Oct 19, 2023 12:50PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:27PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 06, 2018 01:24PM
|
|
Re: Demoralizing....
|
2
|
Resverlogix Corp.
|
Sep 22, 2017 04:01PM
|
